Cardiovascular Drugs Market

1. Cardiovascular Drugs Market Trends, Size, Share, Demands, Overview, Growth, Revenue and Forecast to 2030 sales@delvens.comwww.delvens.com

2. Sternal Closure Systems Market – Trends Forecast Till 2030 Cardiovascular Drugs Market, by Drug Class (Anti-hyperlipidaemic, Anti-hypertensives, Anti-coagulants, Anti-arrhythmic and Others), Indication (Hypertension, Hyperlipidaemia, Coronary Artery Disease, Arrhythmia and Others), Distribution Channel (Hospital, Pharmacies and Others) and region (North America, Europe, Asia-Pacific, Middle East and Africa and South America). Request For Free Sample Report: https://www.delvens.com/get-free-sample/cardiovascular-drugs-market sales@delvens.com www.delvens.com

3. Market Overview Cardiovascular drugs are medications that are used to treat various conditions related to the heart and blood vessels. They are prescribed to manage heart diseases and other cardiovascular disorders. Cardiovascular medicines are often used in combination to treat different aspects of a cardiovascular disease. There are various types of cardiovascular drugs such as antihypertensives that are used to lower blood pressure, anticoagulants that are used to prevent blood clots, antihyperlipidemic that are used to lower cholesterol and triglyceride levels, antiarrhythmics that are used to regulate abnormal heart rhythms. Most cardiovascular drugs are prescribed to treat hypertension and dyslipidaemia which are majorly responsible for the formation of atherosclerotic plaque within blood vessels restricting blood flow to the body parts resulting in multiple cardiac indications such as stroke, heart failure, cardiomyopathy, peripheral artery disease, and venous thrombosis. Purchase this Report: https://www.delvens.com/checkout/cardiovascular-drugs-market sales@delvens.com www.delvens.com

4. Market Overview The cardiovascular drugs market can be segmented based on drug class into anti-hyperlipidaemic, anti-hypertensives, anti-coagulants, anti-arrhythmic and others. Based on indication the market can be bifurcated into hypertension, hyperlipidaemia, coronary artery disease, arrhythmia and others. Based on distribution channel, the market can be segmented into hospital, pharmacies and others.  Rising prevalence of cardiovascular diseases (CVDs) globally, growing research and development and investment in efficient drug development and increasing availability of reimbursement policies are the factors that are contributing to the growth of the market during the forecast period. Moreover, the increasing number of admissions in hospitals, as well as critical care units owing to cardiovascular diseases (CVDs) has created demand for the development of cardiovascular drugs for treatment. sales@delvens.com www.delvens.com

5. Key Findings The Cardiovascular Drugs Market is segmented into various segments such product, procedure, material, fixation technique, end user and region: Based on drug class the market can be segmented into anti-hyperlipidaemic, anti-hypertensives, anti-coagulants, anti-arrhythmic and others. Based on indication, the market can be bifurcated into hypertension, hyperlipidaemia, coronary artery disease, arrhythmia and others. On the basis of distribution channel, the market can be segmented into hospitals, pharmacies and others. sales@delvens.com www.delvens.com

6. Key Findings The hospitals segment dominated the market in this segment which can be attributed to the high demand for cardiovascular drugs in the hospital. The market is also divided into various regions such as North America, Europe, Asia-Pacific, South America, and Middle East and Africa. North America is estimated to account for the largest market share during the forecast period. Inquire Before Buying: https://www.delvens.com/Inquire-before-buying/cardiovascular-drugs-market sales@delvens.com www.delvens.com

7. Competitive Landscape • Amgen Inc • Baxter • Bayer AG • Boehringer Ingelheim International GmbH • F. Hoffmann-La Roche Ltd • Gilead Sciences Inc • Johnson & Johnson • Lupin • Merck & Co., Inc. (MSD) • Novartis AG • Pfizer Inc. • Sanofi S A • Bristol-Myers Squibb Company • AstraZeneca • Janssen Pharmaceuticals, Inc. • Daiichi Sankyo • Portola Pharmaceuticals • United Therapeutics Corp sales@delvens.com www.delvens.com

8. Recent Developments • In May 2022, Amgen revealed positive data from the Phase 2 OCEAN(a)-DOSE clinical study, evaluating olpasiran (formerly AMG 890) in 281 adult patients with Lipoprotein(a), or Lp(a), levels over 150 nmol/L and evidence of atherosclerotic cardiovascular disease (ASCVD). Olpasiran is a small interfering RNA designed to lower the body's production of apolipoprotein(a), a key component of Lp(a) that has been associated with an increased risk of cardiovascular events. • In February 2022, the Food and Drug Administration (FDA) expanded its approval of empagliflozin (Jardiance) for use in adults with heart failure (HF), regardless of ejection fraction, to reduce the risk of cardiovascular death and HF hospitalization. The medication was approved in August 2021 to reduce the risk of cardiovascular death and HF hospitalization in adults with HF with reduced ejection fraction (HFrEF). sales@delvens.com www.delvens.com

9. Contact Information About Us: Delvens is a strategic advisory and consulting company headquartered in New Delhi, India. The company holds expertise in providing syndicated research reports, customized research reports and consulting services. Delvens qualitative and quantitative data is highly utilized by each level from niche to major markets, serving more than 1K prominent companies by assuring to provide the information on country, regional and global business environment. We have a database for more than 45 industries in more than 115+ major countries globally. Contact Us: +44-20-8638-5055 sales@delvens.com WEBSITE: https://delvens.com/ sales@delvens.com www.delvens.com